Tag: vector

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

Winner Chao Wang of Arizona State University will receive $150,000 to evaluate a unique diagnostic that uses gold nanoparticles and has been proven in other infectious diseases

Winner Chao Wang of Arizona State University will receive $150,000 to evaluate a unique diagnostic that uses gold nanoparticles and has been proven in other infectious diseases

Leading Pest Control Company Encourages Action Ahead of National Mosquito Control Awareness Week VIRGINIA BEACH, Va., June 12, 2025 /PRNewswire/ -- As the nation prepares...

- Enables streamlined stability testing and release of higher quality AAV-based gene therapy products. - Provides much needed European capacity for AAV characterization and release. ROCKVILLE,...

Flexible integrations provide choice, control, and interoperability to achieve greater value from enterprise AI initiatives BURLINGTON, Mass., June 10, 2025 /PRNewswire/ -- Precisely, the global...

VIENNA, Va., June 10, 2025 /PRNewswire/ -- Seekr, the trusted AI company, has launched SeekrFlow Agents, a full-stack solution for deploying intelligent agents securely,...

BOSTON, June 9, 2025 /PRNewswire/ -- Taiwan Cell Manufacturing Company (tcmc), a leading Contract Development and Manufacturing Organization (CDMO) in cell and gene therapy...